Key Takeaways
- Aflibercept 8 mg improved visual acuity and reduced retinal thickness over 1 year in most patients with treatment-naïve nAMD.
- Nearly 11% of eyes developed intraocular inflammation with retinal vasculitis during the loading phase, leading to treatment discontinuation.
Intravitreal aflibercept 8 mg administered with a loading phase followed by a treat-and-extend regimen improved visual acuity and reduced retinal and choroidal thickness over 1 year in patients with treatment-naïve neovascular age-related macular degeneration (nAMD), according to a study.
The study evaluated 83 eyes from 80 consecutive patients with treatment-naïve nAMD. Sixty eyes (72.3%) completed 1 year of treatment with aflibercept 8 mg. Among these patients, best-corrected visual acuity improved significantly, whereas foveal thickness and central choroidal thickness were significantly reduced through the 1-year follow-up period.
Patients who completed treatment received an average of 6.5 ± 0.7 injections over 1 year. The intended injection interval at the final visit averaged 13.4 ± 3.3 weeks.
Twenty-three eyes (27.7%) did not complete the 1-year treatment course. Nine eyes (10.8%) developed non-infectious intraocular inflammation associated with retinal vasculitis during the loading phase, resulting in treatment discontinuation. Another 7 eyes (8.4%) were switched to intravitreal brolucizumab because exudative changes persisted despite 8-week aflibercept 8 mg injections during maintenance therapy. The remaining 7 eyes (8.4%) dropped out of treatment.
Reference
Matsumoto H, Hoshino J, Numaga S, et al. One-year outcomes of treat-and-extend regimen with intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2026;doi: 10.1007/s10384-026-01356-x. Epub ahead of print. PMID: 42154378.
Related Content
